Last reviewed · How we verify
7-valent pneumococcal-OMPC conjugate vaccine
7-valent pneumococcal-OMPC conjugate vaccine is a Biologic drug developed by Finnish Institute for Health and Welfare. It is currently in Phase 3 development.
At a glance
| Generic name | 7-valent pneumococcal-OMPC conjugate vaccine |
|---|---|
| Sponsor | Finnish Institute for Health and Welfare |
| Modality | Biologic |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 7-valent pneumococcal-OMPC conjugate vaccine CI brief — competitive landscape report
- 7-valent pneumococcal-OMPC conjugate vaccine updates RSS · CI watch RSS
- Finnish Institute for Health and Welfare portfolio CI
Frequently asked questions about 7-valent pneumococcal-OMPC conjugate vaccine
What is 7-valent pneumococcal-OMPC conjugate vaccine?
7-valent pneumococcal-OMPC conjugate vaccine is a Biologic drug developed by Finnish Institute for Health and Welfare.
Who makes 7-valent pneumococcal-OMPC conjugate vaccine?
7-valent pneumococcal-OMPC conjugate vaccine is developed by Finnish Institute for Health and Welfare (see full Finnish Institute for Health and Welfare pipeline at /company/finnish-institute-for-health-and-welfare).
What development phase is 7-valent pneumococcal-OMPC conjugate vaccine in?
7-valent pneumococcal-OMPC conjugate vaccine is in Phase 3.